Natalie Alba Email

Research Associate II Pharmacology . Parvus Therapeutics

South San Francisco, CA

Location

n****@parvustx.com

Primary Email

Current Roles

Employees:
23
Revenue:
$3.6M
About
Parvus is pioneering an innovative class of disease-modifying therapeutics - Navacims™ - with best-in-disease potential. Current treatment approaches to autoimmune disease generally require suppression of the immune system to prevent immune attack against a patient's own tissues. In contrast, Navacims represent a paradigm shift in treatment approach wherein the immune system is restored to a balanced ‘response ready' and immune self-tolerant state thru the induction and abundant systemic expansion of disease-specific type 1 regulatory T (TR1) cells. Parvus has demonstrated disease reversal with Navacims in multiple in vivo disease models. Two programs are advancing toward the clinic, the first targeting type 1 diabetes (partnered with Novartis) and the second targeting primary biliary cholangitis (PBC), a progressive disease characterized by chronic inflammation, scarring, and destruction of the bile ducts leading eventually to liver failure.
Parvus Therapeutics Address
800 Dubuque Avenue
South San Francisco, CA
United States
Parvus Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.